This characteristic positions mirvetuximab soravtansine as a viable and well-tolerated option, particularly for individuals who may have exhausted other treatment alternatives.[20] The ability to maintain a positive safety profile while providing meaningful therapeutic effects is a crucial aspect in the context of managing advanced ovarian cancer.[21] Similarly, Martin et al (2017) study contributes a valuable perspective by emphasizing the reliability of archival tissue for identifying FRα-positive tumors. This evidence concerns the gene FOLR1 and ovarian carcinoma.